Everything below concerns peptide research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-23. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Blood–brain barrier permeability === Beta blockers vary in their lipophilicity (fat solubility) and in turn in their ability to cross the blood–brain barrier and exert effects in the central nervous system. Beta blockers with greater blood–brain barrier permeability can have both neuropsychiatric therapeutic benefits and side effects, as well as adverse cognitive effects. Central nervous system-related side effects and risks of beta blockers may include fatigue, depression, sleep disorders (namely insomnia) and nightmares, visual hallucinations, delirium, psychosis, Parkinson's disease, and falling. Conversely, central nervous system-related benefits of beta blockers may include prevention and treatment of migraine, essential tremor, akathisia, anxiety, post-traumatic stress disorder, aggression, and obsessive–compulsive disorder. Most beta blockers are lipophilic and can cross into the brain, but there are a number of exceptions. Highly lipophilic beta blockers include penbutolol, pindolol, propranolol, and timolol, moderately lipophilic beta blockers include acebutolol, betaxolol, bisoprolol, carvedilol, metoprolol, and nebivolol, and low lipophilicity or hydrophilic beta blockers include atenolol, carteolol, esmolol, labetalol, nadolol, and sotalol. It is thought that highly lipophilic beta blockers are able to readily cross into the brain, moderately lipophilic beta blockers are able to cross to a lesser degree, and low lipophilicity or hydrophilic beta blockers are minimally able to cross.
=== Completed === A single-arm, phase II trial (003-A1) of carfilzomib in patients with relapsed and refractory multiple myeloma showed that single-agent carfilzomib demonstrated a clinical benefit rate of 36% in the 266 patients evaluated and had an overall response rate of 22.9% and median duration of response of 7.8 months. The FDA approval of carfilzomib was based on results of the 003-A1 trial. In a phase II trial (004), carfilzomib had a 53% overall response rate among patients with relapsed and/or refractory multiple myeloma who had not previously received bortezomib. This study also included a bortezomib-treated cohort. Results were reported separately. This study also found prolonged carfilzomib treatment was tolerable, with approximately 22% of patients continuing treatment beyond one year. The 004 trial was a smaller study originally designed to investigate the impact of carfilzomib treatment in relationship to bortezomib treatment in less heavily pretreated (1–3 prior regimens) patients. A phase II trial (005), which assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, in patients with multiple myeloma and varying degrees of renal impairment, where nearly 50% of patients were refractory to both bortezomib and lenalidomide, demonstrated that pharmacokinetics and safety were not influenced by the degree of baseline renal impairment. Carfilzomib was tolerable and demonstrated efficacy.
In April 2025, Hegseth issued a directive to the secretary of the Army ordering on a sweeping overhaul, prioritizing defending the homeland and deterring China in the Indo-Pacific. Among others, the directive instructing a consolidated budget lines in unmanned systems, counter-drone systems and electronic warfare, force structure changes and expanded use of other transaction agreements. The directive also instructed to downsize or close redundant headquarters as well as merging Army Futures Command and Training and Doctrine Command, and merging four-star headquarters Army Forces Command with Army North and Army South into a single headquarters focused on homeland defense as well as the elimination of at least 20% of four-star general positions to enhance efficiency and operational effectiveness. Hegseth also signed a memorandum to reduce the Department of Defense's civilian workforce, aiming to eliminate duplicative efforts and excessive bureaucracy. The initiative includes offering voluntary early retirement and deferred resignation programs to incentivize top performers and enhance efficiency. That month, Hegseth received criticism from some Senate Democrats over alleged civilian deaths in the Yemen strikes.
== Bite == It is a common misconception that P. phalangioides is incapable of biting humans due to an inability of their fangs to penetrate the human epidermis. These spiders can bite humans since their fangs are roughly 0.25 mm long, while the thickness of the human epidermis is less, around 0.1 mm thick; however, there are hardly any reports on bites.
Seafood is consumed all over the world; it provides the world's prime source of high-quality protein: 14–16% of the animal protein consumed worldwide, with over one billion people reliant on seafood as their primary source of animal protein. Fish is among the most common food allergens. Since 1960, annual global seafood consumption has more than doubled to over 20 kg per capita. Among the top consumers are Korea (78.5 kg per head), Norway (66.6 kg) and Portugal (61.5 kg). The UK Food Standards Agency recommends that at least two portions of seafood should be consumed each week, one of which should be oil-rich. There are over 100 different types of seafood available around the coast of the UK. Oil-rich fish such as mackerel or herring are rich in long-chain omega-3 oils. These oils are found in every cell of the human body, and are required for human biological functions such as brain functionality. Whitefish such as haddock and cod are very low in fat and calories which, combined with oily fish rich in omega-3 such as mackerel, sardines, fresh tuna, salmon and trout, can help to protect against coronary heart disease, as well as helping to develop strong bones and teeth. Shellfish are particularly rich in zinc, which is essential for healthy skin and muscles as well as fertility. Casanova reputedly ate 50 oysters a day.
Sources: en.wikipedia.org
== As an oncolytic agent == Sendai virus-based anticancer therapy for model and companion animals has been reported in several scientific papers. The described studies demonstrate that Sendai virus has a potential of becoming a safe and effective therapeutic agent against a wide range of human cancers. High genomic stability of SeV is a very desirable trait for oncolytic viruses. SeV is not likely to evolve into a pathogenic strain or into a virus with decreased oncolytic potential. The cytoplasmic replication of the virus results in a lack of host genome integration and recombination, which makes SeV safer and more attractive candidate for broadly used therapeutic oncolysis compared to some DNA viruses or retroviruses.
Upon arriving at 25,000 ft, students are removed from their oxygen supply two at a time, for around 2 to 3 minutes. During this time, they will be asked to complete simple tasks such as copying shapes on a piece of paper. They are asked during the time off oxygen how they feel. After being placed back on oxygen, they will understand how their judgement was impaired during the time that they were experiencing hypoxia. The training goes further with rapid decompression profiles, where the chamber is very rapidly ascended from 8,000 ft to 22,000 ft within 10 to 20 seconds, to simulate the loss of a cabin door. For fighter pilots this is done from an altitude of 25,000 ft to 43,000 ft within 5 seconds which simulates the loss of a fighter aircraft's canopy. Hypobaric chambers are also finding increasing use as a means of improving athletic performance. Since the human body adapts to extended mild hypoxia by increasing the quantity of red cells in the blood and this raises aerobic performance, athletes sleep in them as part of their training regimen. This has roughly the same effect as training in high altitudes, but the use of hypobaric chambers plays into the controversial issue of enhanced athletic performance. Mika LaVaque-Manty asks in his book, "Are hypobaric chambers, which simulate high-altitude conditions, a natural way to improve your body?" This hints that the hypobaric chambers use can be likened to blood doping and thus be deemed an unfair athletic advantage. This could lead to a ban on hypobaric chambers for athletic training.
=== OSS-7: Dash7 open-source stack === The goal of the project is to provide a reference implementation of the DASH7 Alliance protocol. This implementation should focus on completeness, correctness and being easy to understand. Performance and code size are less important aspects. For clarity, a clear separation between the ISO layers is maintained in the code. The project is available on GitHub and is licensed under the Apache License, version 2.0.
== Typical activities == Organized crime groups provide a range of illegal services and goods. Organized crime often victimizes businesses through the use of extortion or theft and fraud activities like hijacking cargo trucks and ships, robbing goods, committing bankruptcy fraud (also known as "bust-out"), insurance fraud or stock fraud (insider trading). Organized crime groups also victimize individuals by car theft (either for dismantling at "chop shops" or for export), art theft, Metal theft, bank robbery, burglary, jewelry and gems theft and heists, shoplifting, computer hacking, credit card fraud, economic espionage, embezzlement, identity theft, and securities fraud ("pump and dump" scam). Some organized crime groups defraud national, state, or local governments by bid rigging public projects, counterfeiting money, smuggling or manufacturing untaxed alcohol (rum-running) or cigarettes (buttlegging), and providing immigrant workers to avoid taxes. Organized crime groups seek out corrupt public officials in executive, law enforcement, and judicial roles so that their criminal rackets and activities on the black market can avoid, or at least receive early warnings about, investigation and prosecution. Activities of organized crime include:
== Other abbreviating conventions == In some health care institutions, house rules deprecate the standard symbol for microgram, "μg", in prescribing or chart recording, because of the risk of giving an incorrect dose because of the misreading of poor handwriting. The two alternatives are to abbreviate as "mcg" or to write out "microgram" in full (see also List of abbreviations used in medical prescriptions). The alternative abbreviation may be ambiguous in rare circumstances in that mcg could also be read as a micrigram, i.e. 10−14 g; however the prefix micri is not standard, nor widely known, and is considered obsolete. This deprecation, focused on avoiding incorrect dosing in contexts where handwriting is often present, does not extend to all health-care contexts and institutions (for example, some clinical laboratories' reports adhere to it, whereas others do not), and in physical sciences research, "μg" remains the sole official abbreviation. In medical data exchange according to the Health Level 7 (HL7) standard, the μ can be replaced by u as well.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.